XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1

Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2024

Segment Reporting [Abstract]

Sales from Products

Sales of the Company’s products were as follows:

			Three Months Ended March 31,
			2024																		2023
($ in millions)			U.S.						Int’l						Total						U.S.						Int’l						Total
Pharmaceutical:
Oncology
Keytruda			$	4,119					$	2,828					$	6,947					$	3,485					$	2,310					$	5,795
Alliance revenue-Lynparza (1)			135						157						292						142						133						275
Alliance revenue-Lenvima (1)			173						82						255						153						79						232
Welireg			77						7						85						41						1						42
Alliance revenue-Reblozyl (2)			58						12						71						30						12						43
Vaccines
Gardasil/Gardasil 9			488						1,761						2,249						416						1,556						1,972
ProQuad/M-M-R II/Varivax			438						133						570						421						107						528
Vaxneuvance			161						58						219						94						13						106
RotaTeq			149						67						216						180						117						297
Pneumovax 23			6						55						61						40						56						96
Hospital Acute Care
Bridion			329						111						440						276						210						487
Prevymis			74						100						174						54						75						129
Dificid			68						5						73						62						3						65
Zerbaxa			33						23						56						27						23						50
Noxafil			8						48						56						14						46						60
Cardiovascular
Alliance revenue-Adempas/Verquvo (3)			90						8						98						83						16						99
Adempas			—						70						70						—						59						59
Virology
Lagevrio			45						305						350						(2)						394						392
Isentress/Isentress HD			50						61						111						52						71						123
Delstrigo			12						44						56						11						33						44
Pifeltro			29						13						42						24						10						34
Neuroscience
Belsomra			15						32						46						16						40						56
Immunology
Simponi			—						184						184						—						180						180
Remicade			—						39						39						—						51						51
Diabetes
Januvia			183						236						419						271						280						551
Janumet			39						212						251						56						272						329
Other pharmaceutical (4)			157						419						576						171						457						626
Total Pharmaceutical segment sales			6,936						7,070						14,006						6,117						6,604						12,721
Animal Health:
Livestock			166						683						850						174						676						849
Companion Animal			308						354						661						308						334						642
Total Animal Health segment sales			474						1,037						1,511						482						1,010						1,491
Total segment sales			7,410						8,107						15,517						6,599						7,614						14,212
Other (5)			68						190						258						60						214						275
			$	7,478					$	8,297					$	15,775					$	6,659					$	7,828					$	14,487

U.S. plus international may not equal total due to rounding.

(1)    Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).

(2)    Alliance revenue for Reblozyl represents royalties (see Note 3).

(3)    Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3).

(4)    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.

(5)    Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased sales by $54 million and $99 million for the three months ended March 31, 2024 and 2023, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the three months ended March 31, 2024 and 2023 also includes $61 million and $51 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.

Consolidated Sales by Geographic Area

Consolidated sales by geographic area where derived are as follows:

			Three Months Ended March 31,
($ in millions)			2024						2023
United States			$	7,478					$	6,659
Europe, Middle East and Africa			3,563						3,303
China			1,772						1,715
Japan			821						758
Latin America			796						661
Asia Pacific (other than China and Japan)			724						846
Other			621						545
			$	15,775					$	14,487

Reconciliation of Segment Profits to Income before Taxes

A reconciliation of segment profits to Income Before Taxes is as follows:

			Three Months Ended March 31,
($ in millions)			2024						2023
Segment profits:
Pharmaceutical segment			$	10,904					$	9,140
Animal Health segment			555						566
Total segment profits			11,459						9,706
Other profits			146						164
Unallocated:
Interest income			73						112
Interest expense			(303)						(242)
Amortization			(473)						(543)
Depreciation			(452)						(398)
Research and development			(3,851)						(4,147)
Restructuring costs			(123)						(67)
Charge for Zetia antitrust litigation settlements			—						(573)
Other unallocated, net			(806)						(362)
			$	5,670					$	3,650

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration